Product logins

Find logins to all Clarivate products below.


Coronavirus COVID-19 – Epidemiology – Coronavirus COVID-19 Forecaster

The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global COVID-19 forecasts for up to two years from initial outbreak. Base assumptions used in this model have been tested and developed by DRG’s Epidemiology team using a semi-mechanistic methodology, running thousands of simulations with plausible parameter ranges set out by the current literature and benchmarked using daily reported COVID-19-related mortality data from the European Centre for Disease Prevention and Control (ECDC) using goodness-of-fit analysis.
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0cm;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:ZH-CN;}

Forecasting COVID-19 is challenging for several reasons, including the uncertainty in effect size and duration of local nonpharmaceutical interventions and the timing and efficacy of different treatments entering the market. Therefore, DRG’s COVID19 Epidemiology Forecaster is flexible by design. Each variable used in the model is fully adjustable, and the tool allows the addition of up to five interventions. The COVID-19 Epidemiology Forecaster reports the following metrics in a tabular form, as well as in a variety of data visualization graphics:

  • Total case estimates (everyone infected with the virus, including laboratory-confirmed and -unconfirmed cases).
  • Mortality associated with COVID-19.
  • Adjusted infection fatality rate to allow cross-country comparisons.
  • Incident and cumulative hospitalizations.
  • Incident and cumulative intensive care unit (ICU) admissions.
  • Available in both total and age-stratified formats.

The COVID-19 Epidemiology Forecaster allows users to export diagrams and charts as image files that can easily be incorporated into internal or investor/shareholder material.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…